A Phase 1 interventional study of MK-4482 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.
Among the 14 studies testing molnupiravir in COVID-19, this one is the 14th largest by enrollment, is the only one that started in 2023, is the only one in phase 1, and was the 14th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Liverpool · Sites in South Africa, United Kingdom
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 60 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2020; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 275 across the 14 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
11 studies in COVID-19 by Merck & Co., Inc: 1 open now, 1 under way, 1 of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 11 studies in COVID-19 by Merck & Co., Inc, this one is the 10th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 1, and was the 11th registered.
Merck & Co., Inc’s COVID-19 studies by the year they started, since 2020.
2 of the studies testing molnupiravir in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing molnupiravir in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 11 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
- Has a (BMI) of 19 to 24 weight (kg)/height (m)2, inclusive, and body weight of ≥ 50 kg at the screening visit.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
Drug: MK-4482
Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
The Maximum Observed Plasma Concentration (Cmax) After Single Oral Dose of MK-4482 in Period 1
Cmax of N-hydroxycytidine (NHC) after a single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Single Oral Dose of MK-4482 in Period 1.
Tmax of NHC following single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Elimination Half Life (T1/2) After Single Oral Dose of MK-4482 in Period 1
T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after a single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Apparent Total Clearance (CL/F) After Single Oral Dose of MK-4482 in Period 1
CL/F of NHC from plasma after single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Apparent Volume of Distribution (Vz/F) After Single Oral Dose of MK-4482 in Period 1
Vz/F of NHC during terminal phase after single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Single Oral Dose of MK-4482 in Period 1
This is a measure of the average amount of NHC in the plasma over a period of 12 hours after single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration (AUC0-last) After Single Oral Dose of MK-4482 in Period 1
AUC0-last of NHC following a single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
Area Under The Plasma Concentration Versus Time Curve From Time Zero (pre-dose) to Extrapolated Infinite Time (AUC0-inf) After Single Oral Dose of MK-4482 in Period 1
AUC0-inf of NHC after single oral dose of MK-4482 in period 1.
Time frame: At designated time points up to 72 hours post-dose
The Maximum Observed Plasma Concentration (Cmax) After Multiple Oral Doses of MK-4482 in Period 2
Cmax of NHC after multiple oral doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Multiple Oral Doses of MK-4482 in Period 2
Tmax of NHC following multiple oral doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Elimination Half Life (T1/2) After Multiple Oral Doses of MK-4482 in Period 2
T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after multiple oral doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Clearance at Steady State (CLss/F) After Multiple Oral Doses of MK-4482 in Period 2
CLss/F of plasma NHC following multiple doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Apparent Volume of Distribution (Vz/F) After Multiple Oral Doses of MK-4482 in Period 2
Vz/F of NHC during terminal phase after multiple doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Multiple Oral Doses of MK-4482 in Period 2
This is a measure of the average amount of NHC in the plasma over a period of 12 hours after multiple oral doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
The Minimum Concentration (Ctrough) After Multiple Oral Doses of MK-4482 in Period 2
Ctrough of NHC that occurred following multiple doses of MK-4482 in period 2.
Time frame: At designated time points up to 72 hours post-dose
Accumulation Ratio on Cmax After Multiple Oral Doses of MK-4482 in Period 2
The maximum concentration at steady state following multiple doses of MK-4482 in period 2 divided by the maximum concentration following the initial dosing in Period 1.
Time frame: At designated time points up to 72 hours post-dose
Accumulation Ratio on AUC0-12hr After Multiple Oral Doses of MK-4482
The AUC0-12hr at steady state following multiple doses of MK-4482 in period 2 divided by the AUC0-12hr following the initial dosing in Period 1.
Time frame: At designated time points up to 72 hours post-dose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to ~ 5.5 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to ~ 5.5 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2023 to primary completion in Aug 2023, 1 month.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 1 month is below that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir